Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed · Phase 2

Conditions studied: Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma

In brief

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Key facts

Study ID

NCT00003646

Run by

Vical

People needed

78

Starts

1998-08-01

Expected to finish

2002-05-01

Last updated by the study team

2011-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Physician Reliance Network, Inc. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.